The company aims to start a pivotal trial this year, file for 510(k) clearance in 2027 and launch the device in 2028.
Insulet (Nasdaq:PODD) shared new clinical evidence for its first fully closed-loop automated insulin delivery system for type 2 diabetes.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results